Auspex Pharmaceuticals Announces Positive Results From Clinical Study Of SD-254, A Next-Generation Potential Treatment For Depression

Posted by on October 29th, 2008 at 05:00am

Auspex Pharmaceuticals, a developer of next-generation medicines with improved safety and performance through the targeted deuteration of clinically validated drugs, today announced positive results from its Phase 1 clinical trial evaluating SD-254, a Selective Serotinin-Norepinephrine Reuptake Inhibitor (SNRI). Auspex is developing SD-254, a deuterium-substituted version of venlafaxine, for the treatment of Major Depressive Disorder.

Spread the Love & Syndicate
  • del.icio.us
  • YahooMyWeb
  • digg
  • Furl
  • description
  • De.lirio.us
  • co.mments
  • Ma.gnolia
  • Reddit
  • Spurl
  • Northstar Neuroscience Receives FDA Approval For A Clinical Study Of Its Cortical Stimulation System For The Treatment Of Major Depressive Disorder
  • American College Of Physicians Finds No Substantial Differences Among "Second-Generation" Antidepressant Drugs
  • Can We Identify Depressed Patients Who Are Not Going To Respond To Drug Treatment?
  • 3 Types of Depression

    • Under Depression

    Leave a Comment for Auspex Pharmaceuticals Announces Positive Results From Clinical Study Of SD-254, A Next-Generation Potential Treatment For Depression

    Required

    Required, hidden

    Trackback this post  |  Subscribe to the comments via RSS Feed

    Recent Blog Posts

    Categories

    Posts by Month

    Resources